High barrier elastomer fecal catheter or ostomy pouch

Information

  • Patent Grant
  • 11806270
  • Patent Number
    11,806,270
  • Date Filed
    Wednesday, November 24, 2021
    2 years ago
  • Date Issued
    Tuesday, November 7, 2023
    5 months ago
Abstract
Certain embodiments relate to a soft odor barrier material in a medical device. The soft odor barrier material includes an elastomer and an antiblocking agent. In certain forms, the antiblocking agent imparts an interior rough surface having an arithmetic mean surface roughness (Ra) not less than 0.1 μm. In certain forms, the antiblocking agent is non-blocking upon folding and packaging.
Description
FIELD OF THE INVENTION

The present invention relates to an odor barrier material for a fecal catheter, a fecal pouch, or an ostomy pouch.


BACKGROUND OF THE INVENTION

Fecal catheters have occasionally been criticized for the transmission of fecal odor through the tubular walls.


A possible cause of the poor odor barrier is the silicone material of which these devices are composed. The odor barrier of silicone is known to be one of the worst among polymer materials. For example, the oxygen transmission rate of silicone has been reported to be 775,000 cc mil/m2/day. Therefore, a 20 mil thick silicone catheter is about 3 orders of magnitude worse than a commonly used ostomy film having a transmission rate of 50 cc/m2/day or less.


Another possible explanation for silicone fecal catheter having poor odor barrier is that the extruded silicone utilized in such devices is relatively rough and as a result could trap fecal components. The contours of the spots trapping the fecal material provide substantial surface area, through which odor is transmitted.


The combination of high odor transmission rate and large surface area contributes to the poor odor barrier characteristics of the silicone used in fecal catheters.


It would be desirable to develop a material to be used in a fecal catheter that has the desirable characteristics of silicone while providing an odor barrier substantially better than that of silicone.


It is the object of the present invention to provide an odor barrier polymer having these characteristics.







DESCRIPTION OF THE INVENTION

Thermoplastic elastomer (TPE) or curable elastomer is well known for use in medical devices. However, these elastomers are not known to exhibit high odor barrier properties. The present invention is the modification of elastomer to achieve a high odor barrier while maintaining its softness, ability for post extrusion converting (welding and bonding) and non-blocking characteristics.


One embodiment of the present invention related to single layer of catheter made from a high barrier elastomer such that the odor barrier measured by oxygen transmission rate per ASTM D3985 is not more than 50,000 cc mil/m2/day at 23° C., or more preferably not more than 5,000 cc mil/m2/day. Such a catheter is at least 10 times better in odor barrier than the silicone catheter.


U.S. Pat. Nos. 6,946,522, 7,056,971, and 7,060,753 disclosed the use of a liquid polyisobutene oil plasticizer to improve the gas barrier of the TPE. However, these formulations, especially when targeting a soft elastomer, i.e., Shore A less than 60, creates a blocking issue in which the surface of TPE catheter seals against each other upon folding and packaging. The use of a higher amount of oil plasticizer would allow a softer TPE, but it comes with an adverse effect in an oily surface, resulting in poor post-extrusion converting (welding and bonding). In addition, the TPE based on an olefin block copolymer (OBC, such as Infuse™ made by Dow) was not disclosed. Although common approaches exist to minimize the blocking, including adding mineral oil or slip additives. These approaches; however, have drawbacks in that they prevent the parts from being further converted into a fecal catheter due to their adverse effects on the surface bonding. U.S. Pat. No. 7,629,406 disclosed the use of an organoclay at a concentration less than 4% to improve the barrier properties of high density polyethylene (HDPE). However, the use of organoclay in a TPE was not mentioned with a Shore A hardness not more than 60, or preferably not more than 50.


Another embodiment of the present invention is related to a fecal catheter, having a Shore A hardness not more than 60 and an oxygen transmission rate not more than 2,500 cc/m2/day or preferably not more than 1,000 cc/m2/day, comprising (1) a thermoplastic elastomer, (2) odor barrier modifier, and (3) an antiblocking agent of at least 0.1%, wherein thermoplastic elastomer is selected from the group consisting of a styrenic block copolymer, a thermoplastic vulcanizate, or a polyolefin elastomer, and wherein odor barrier modifier is selected from the group consisting of polyisobutene, polybutene, or an organoclay, and wherein the antiblocking agent is selected from the group consisting of an essentially inorganic fillers, such as silica, talc, clay, mica, etc. and blends thereof. It is noted organoclays can be used in one embodiment as both the odor barrier modifier and as the antiblocking agent. Organoclays include montmorillonite clay, smectite clay, intercalated clay, nanoclay, or a mixture of above. Organoclay described in this invention includes montmorillonite clay, made by Nanocor, which is the most common member of the smectite clay family. Organoclay may consist of nanoclay with a unique morphology such that one dimension is in the nanometer range. In addition, organoclay is preferred to be intercalated with an organic intercalant resulting in a clay-chemical complex wherein the clay gallery spacing has increased due to the process of surface modification. Under the proper conditions of temperature and shear, an intercalate is capable of exfoliating in a resin matrix. Optionally, the following additives can be used to facilitate the manufacturing of catheter extrusion, including melt viscosity modifier, tackifier, detackifier, plasticizer, etc.


Styrenic block copolymer (SBC) based thermoplastic elastomer includes styrene-isoprene-styrene (SIS), styrene-butadiene-styrene (SBS), styrene-ethylene/butylene-styrene (SEBS), styrene-ethylene/propylene-styrene (SEPS), and blends thereof. Thermoplastic vulcanizate (TPV) includes a blend of curable rubber and a polyolefin (i.e., PP or PE, homopolymers and copolymers). Curable rubbers include EPDM, EP rubber, santoprene, etc. A polyolefin elastomer includes an olefin block copolymer (OBC), such as Infuse made by Dow, where a crystalline phase of a olefin block copolymer acted as hard blocks, and the amorphous block copolymer acted as soft blocks within the same polymer matrix. The following is a summary of odor barrier as measured by oxygen transmission rate at 23° C. per ASTM D3985:









TABLE 1







Odor Barrier Comparison of Various Elastomers without Organoclays or zeolites



















SBC







SBC
w/polyisobutene



Silicone
SBC
TPV
OBC
w/polyisobutene
and Organoclay

















OTR,
37,500
2.500-4.500
2,500
2,500
1,000
250


cc/m2/day,


20 mil thick


wall, ASTM


D3985


Onion
Very poor,
Poor,
Poor,
Poor,
Better,
Good,


Barrier,
detectable
detectable
detectable
detectable
detectable
not detectable


ISO 8670-3
in 10
in 60
in 60
in 60
in 120
for 8



minutes
minutes
minutes
minutes
minutes
hrs









When antiblocking agent, at least 0.1% or more preferably more than 0.5%, was added to a high barrier elastomer formulation containing a SBC thermoplastic elastomer and a liquid polyisobutene, an odor barrier in the range of around 1000 cc/m2/day was achieved for making a non-blocking fecal catheter. This level of odor barrier improvement was confirmed by an onion test per ISO 8670-3 such that the onion odor breakthrough was longer than 120 minutes. Additional barrier improvement was seen in fecal catheter made from PTE containing a SBC thermoplastic elastomer, a liquid polyisobutene, an organoclay. In this example, onion odor breakthrough was longer than 8 hours. The results of both oxygen barrier and onion barrier were shown in Table 1.


Another embodiment of the present invention is a fecal catheter based on a multilayer structure, wherein at least one layer is selected from a high barrier elastomer described above without any antiblocking agent, and at least another skin layer is selected from the group consisting of (1) same high barrier elastomer described above with at least 0.1% of antiblocking agent, or an elastomer alloy with or without the use of antiblocking agent. An elastomer alloy is defined as a blend of two polymer matrixes which are incompatible in a molecular level. The advantage of antiblocking agent is to impart a rough surface so that the catheter is not blocking. The advantage of an elastomer alloy is that the incompatibility in a molecular level creates a roughness on the catheter surface, giving rise to a non-blocking catheter. In addition, common materials to add for an elastomer alloy include, but not limited to, thermoplastic polyurethane (TPU). Due to a more polar structure in TPU, the subsequent converting of an elastomer alloy is easier. Since the majority of the catheter structure is provided by a high barrier elastomer, the odor barrier and the softness is maintained based on the disclosure above. Because both the center layer and the skin layer are elastomers based, the adhesion between the layers of a fecal catheter is sufficiently good.


Besides the addition of anti-blocking agent, cold processing conditions can be utilized to enhance a rough surface of the catheter wall so that the catheter is not blocking. The effect of anti-blocking agent and/or cold processing conditions is a rough surface that could be characterized by surface roughness using a non-contact surface structure analyzer, such as Scanning White Light interferometry (SWLI), Atomic Force Microscopy (AFM), etc. A non-contact imaging surface structure analyzer based on SWLI is made by Zygo NewView 7300. A non-contact atomic force microscopy can be made by FEI. A typical parameter that has been used to quantify the quality of a surface topography is the surface roughness, which is represented by the arithmetic mean value, Ra. In this invention disclosure, a rough surface with Ra not less than 0.1 μm or preferably not less than 1 μm when antiblocking agent is used with or without a cold processing temperature, resulted in a non-blocking fecal catheter.


An important characteristic about the formulation described in this invention is its ability to be post-extrusion converted, both by welding and adhesive bonding. Greater than 5 N/in adhesive strength and heat weld strength was achieved.


Another embodiment of the present invention is related to the use of organoclays and/or zeolites to improve the odor barrier of the elastomer catheter. For example, a single layer of catheter can be made from an organoclay-containing elastomer selected from the group consisting of silicone, polyurethane, styrenic block copolymer, thermoplastic vulcanizate, or polyolefin elastomer with a Shore A hardness not more than 60, or more preferably not more than 50.


The use of nanocomposite (nanoclays) fillers to improve the odor barrier is not new. The addition of nanocomposite fillers creates the tortuous path for the odor causing compounds; thus improving the odor barrier for the substrate. There are various nanocomposite containing coating, additives, or polymers marketed by various companies, such as Nanocor, Nanoresin, Southern Clays, Nano-X, Inmat, etc. Since nanocomposites are mostly clay based, it is relatively rigid. Therefore, the challenges of using nanocomposite fillers in FMS application are two fold, (1) the difficulty in the wetting and adhesion of the nanocomposite fillers or coating onto the silicone tubing, and (2) the odor barrier property upon flexing. Therefore, the uniqueness of this invention is the formulation of a soft tube with a completely covered, and/or relatively uniformly dispersed nanocomposite containing catheter which would not crack upon flexing. Such a soft nanoclay-containing catheter is characterized with a Shore A hardness not more than 60, or more preferably not more than 50.


Another embodiment of the present invention is related to single layer of catheter made from a zeolite-containing elastomer selected from the group consisting of silicone, polyurethane, styrenic block copolymer, thermoplastic vulcanizate, or polyolefin elastomer with a Shore A hardness not more than 60, or more preferably not more than 50.


The addition of zeolite creates the tortuous paths and sites to adsorb the odor causing compounds; thus improving the odor barrier for the substrate. There are various zeolites marketed by various companies, such as UOP. Since zeolites are hard fillers, they produce rigidity when used. Therefore, the challenges of using zeolites in FMS application are two fold, (1) the difficulty in the wetting and adhesion of the zeolite coating onto the silicone tubing, and (2) the odor barrier property upon flexing. Therefore, the uniqueness of this invention is the formulation of a soft tube with relatively uniform zeolite-containing elastomeric catheter which would not crack upon flexing. Such a soft zeolite-containing catheter is characterized with a Shore A hardness not more than 60, or more preferably not more than 50.


Another embodiment of the present invention is related to an organoclay-containing coating onto an elastomer substrate selected from the group consisting of silicone, polyurethane, styrenic block copolymer, thermoplastic vulcanizate, or polyolefin elastomer with a Shore A hardness not more than 60, or more preferably not more than 50.


Another embodiment of the present invention is related to a zeolite-containing coating onto an elastomer substrate selected from the group consisting of silicone, polyurethane, styrenic block copolymer, thermoplastic vulcanizate, or polyolefin elastomer with a Shore A hardness not more than 60, or more preferably not more than 50.


A series of experiments were conducted as described below. A total of four different nanocomposites were evaluated, two from Southern Clay and two from Nanocor. Two types of coating matrix were used, silicone and polyurethane. The following is a summary of these findings:


Exp. #1: Silicone Coating Consisting of Nanocomposites

2.5% of the following nanocomposites were added into a two-part silicone made by Nusil 6350, including


(1) Southern Clay Cloisite Na+, Hydrated Aluminum Silicate,


(2) Southern Clay Cloisite 15A, Ammonium salts with Bentonite,


(3) Nanocor 1.30E (Octadecyl ammonium surface compatibilized montmorillonite), and


(4) Nanocor 1.34 TCN (methyl, bis hydroxyethyl octadecyl ammonium surface compatibilized montmorillonite).


The two-part silicone was applied onto the silicone catheter as a coating, and was then heat cured at 130 deg C. for 30 minutes. The coated catheter was then tested for onion odor barrier per ISO 8670-3:2000. About 5 grams of onion was chopped and filled inside a 12 cm long coated silicone tubing (i.e., catheter).















Nanocomposite














Cloisite
Cloisite
Nanocor
Nanocor



None
NA+
15A
1.30E
1.34TCN
















Coating Matrix,
Silicone
Silicone
Silicone
Silicone
Silicone


Nusil 6350


Substrate,
Silicone
Silicone
Silicone
Silicone
Silicone


Dow Corning C6-135


Onset of Onion Smell
5 minutes
45 minutes
45 minutes
90 minutes
60 minutes









As can be seen, the addition of 2.5% nanocomposites in a silicone coating improves the onion odor barrier in the silicone tubing. The control with a silicone coating had an onset of onion odor outside of the closed silicone tubing at around 5 minutes. This is about the same as the silicone tube without any coating. After a silicone coating consisting of 2.5% nanocomposites was applied onto a silicone tube, the onset of the onion odor was extended to 45-90 minutes.


Exp. #2: Polyurethane Coating Consisting of Nanocomposites, without Primer

2.5% of the following nanocomposites were added into a two-part polyurethane made by Smooth-On, Vytaflex 30, including


(1) Southern Clay Cloisite Na+, Hydrated Aluminum Silicate,


(2) Southern Clay Cloisite 15A, Ammonium salts with Bentonite,


(3) Nanocor 1.30E (Octadecyl ammonium surface compatibilized montmorillonite), and


(4) Nanocor 1.34TCN (methyl, bis hydroxyethyl octadecyl ammonium surface compatibilized montmorillonite).


The two-part polyurethane was applied onto the silicone catheter as a coating, and was then room temperature cured for 6 hours. The coated catheter was then tested for onion odor barrier per ISO 8670-3:2000. About 5 grams of onion was chopped and filled inside a 12 cm long coated silicone tubing (i.e., catheter).















Nanocomposite














Cloisite
Cloisite
Nanocor
Nanocor



None
NA+
15A
1.30E
1.34TCN
















Coating Matrix,
Polyurethane
Polyurethane
Polyurethane
Polyurethane
Polyurethane


Vytaflex 30


Primer,
No
No
No
No
No


Dow Corning 1200


Substrate,
Silicone
Silicone
Silicone
Silicone
Silicone


Dow Corning C6-135


Onset of Onion Smell
30 minutes
6 hours
6 hours
>12 hours
>12 hours









As can be seen, the addition of 2.5% nanocomposites significantly improves the onion odor barrier. The control with a polyurethane coating, but without any nanocomposites, was able to extend the onset of onion odor outside of the closed silicone tubing from 5 minutes to 30 minutes. After a polyurethane coating consisting of 2.5% nanocomposites was applied onto a silicone tube, the onset of the onion odor was extended to 6-12 hours. Despite of the odor barrier improvement, the coating adhesion was poor.


Exp. #3: Polyurethane Coating Consisting of Nanocomposites, with Primer

The same set of experiment as Exp. #2 was repeated with the use of a silane primer, Dow Corning 1200. The same level of onion odor improvement was observed. That is, after a polyurethane coating consisting of 2.5% nanocomposites was applied onto a silicone tube primed with a silane, the onset of the onion odor was extended from 30 minutes in the control without any nanocomposites to 6-12 hours. The polyurethane coating stuck well to the silicone tube, and was able to resist the flex.















Nanocomposite














Cloisite
Cloisite
Nanocor
Nanocor



None
NA+
15A
1.30E
1.34TCN
















Coating Matrix,
Polyurethane
Polyurethane
Polyurethane
Polyurethane
Polyurethane


Vytaflex 30


Primer,
Yes
Yes
Yes
Yes
Yes


Dow Corning 1200


Substrate,
Silicone
Silicone
Silicone
Silicone
Silicone


Dow Corning C6-135


Onset of Onion Smell
30 minutes
6.5 hours
6 hours
>12 hours
>12 hours









Exp. #4: Nanocomposites in a Silicone Slab

2% of Nanocor 1.30E was added to make into a 1 mm thick (i.e., 40 mil) silicone gel slab, Nusil 6350. Onion barrier was compared on silicone slab with and without the nanocomposite per ISO 8670-3:2000.
















1 mm thick silicone
1 mm thick silicone



slab without nano-
slab with 2%



composites (control)
Nanocor 1.30E


















Onset of Onion Smell
5-10 minutes
60 minutes









As a result, the addition of 2% of Nanocor 1.30E improved the onion odor barrier of the silicone slab from 5 minutes to about 60 minutes.


Another embodiment of the present invention is an improved odor barrier fecal catheter, having a Hardness of less than Shore A 60, comprising at least (a) one layer of a silane coupling agent, and (b) at least one layer of nanocomposite coating. This formulation, when applied onto a silicone fecal catheter, would result in an oxygen transmission rate no more than 20,000 cc/m2/day, or preferably, no more than 10,000 cc/m2/day, or more preferably no more than 5,000 cc/m2/day. A silicone tube without the use of silane coupling agent and without the nanocomposite coating has an oxygen permeation rate of around 37,500 cc/m2/day. A silicone with the nanocomposite coating, but without the silane coupling agent, has an oxygen permeation rate of close to 30,000-35,000 cc/m2/day due to the lack of bonding. Alternatively, the same formulation can be applied onto a thermoplastic elastomer (TPE) or a polyurethane tubing (PU), having a Hardness of less than Shore A 60, such that the gas barrier is improved to no more than 25,000 cc/m2/day, or preferably, no more than 10,000 cc/m2/day, or more preferably no more than 5,000 cc/m2/day.


The materials described in this invention can be used as a fecal catheter. A fecal pouch is commonly connected to a fecal catheter in use. The same materials described for fecal catheter were used to make a fecal pouch. Similar odor barrier characteristics against oxygen transmission and onion odor shown in Table 1 were obtained in the lab. Thus, besides a fecal catheter, the same material construction could be used for an ostomy pouch.

Claims
  • 1. A soft odor barrier material in a medical device, the soft odor barrier material comprising an elastomer and an antiblocking agent that imparts an interior rough surface having an arithmetic mean surface roughness (Ra) not less than 0.1 μm.
  • 2. The soft odor barrier material of claim 1, wherein the arithmetic mean surface roughness (Ra) is not less than 1 μm.
  • 3. The soft odor barrier material of claim 1, wherein the odor barrier material is non-blocking upon folding and packaging.
  • 4. The soft odor barrier material of claim 1, wherein the elastomer is selected from the group consisting of a silicone, a polyurethane, a styrenic block copolymer, a thermoplastic vulcanizate, and a polyolefin elastomer.
  • 5. The soft odor barrier material of claim 1, further comprising an odor barrier modifier selected from the group consisting of a polyisobutene, a polybutene, and an organoclay.
  • 6. The soft odor barrier material of claim 1, wherein the antiblocking agent is selected from the group consisting essentially of inorganic fillers, including silica, talc, clay, and mica, and any combination thereof.
  • 7. The soft odor barrier material of claim 1, wherein the elastomer comprises a styrenic block copolymer comprising styrene-isoprene-styrene (SIS), styrene-butadiene-styrene (SBS), styrene-ethylene/butylene-styrene (SEBS), styrene-ethylene/propylene-styrene (SEPS), and/or any combination thereof.
  • 8. The soft odor barrier material of claim 1, wherein the elastomer comprises a polyolefin elastomer comprising an olefin block copolymer, wherein a crystalline phase of the olefin block copolymer acts as hard blocks and an amorphous block copolymer acts as soft blocks.
  • 9. The soft odor barrier material of claim 1, wherein the elastomer comprises a thermoplastic vulcanizate comprising a blend of a curable rubber and a polyolefin.
  • 10. The soft odor barrier material of claim 9, (i) wherein the curable rubber is selected from the group consisting of ethylene propylene diene monomer (EPDM), ethylene propylene rubber, santoprene, and blends thereof; or(ii) wherein the polyolefin is polyethylene and polypropylene, including homopolymers and copolymers thereof.
  • 11. The soft odor barrier material of claim 1, further comprising an odor barrier modifier comprising organoclay, wherein the organoclay comprises montmorillonite clay, smectite clay, intercalated clay, nanoclay, or any combination thereof.
  • 12. The soft odor barrier material of claim 1, comprising an odor barrier that is at least 10 times better than silicone, as measured by oxygen transmission rate.
  • 13. The soft odor barrier material of claim 1, comprising an oxygen transmission rate per ASTM D3985 that is 1000 cc/m2/day or less at 23° C.
  • 14. The soft odor barrier material of claim 1, comprising a Shore A hardness of 60 or less.
  • 15. A soft odor barrier material in a medical device, the soft odor barrier material comprising an elastomer and an antiblocking agent that is non-blocking upon folding and packaging.
  • 16. The soft odor barrier material of claim 15, wherein the antiblocking agent imparts an interior rough surface having an arithmetic mean surface roughness (Ra) not less than 0.1 μm.
  • 17. The soft odor barrier material of claim 15, wherein the antiblocking agent imparts an interior rough surface having an arithmetic mean surface roughness (Ra) not less than 1 μm.
  • 18. The soft odor barrier material of claim 15, wherein the odor barrier material can be bonded with an adhesive having an adhesive strength greater than 5 N/in or heat welded having a weld strength greater than 5 N/in.
  • 19. The soft odor barrier material of claim 15, further comprising a nanocomposite filler material coated on or present within the elastomer so as to provide an odor barrier.
  • 20. The soft odor barrier material of claim 19, wherein the elastomer and the nanocomposite filler form a soft catheter tube having a Shore A hardness of not more than 60.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a Continuation of U.S. patent application Ser. No. 16/186,003, filed on 9 Nov. 2018, which is a Continuation of U.S. patent application Ser. No. 14/005,814, filed on 26 Mar. 2014 (now U.S. Pat. No. 10,166,137), which is a national stage entry of International PCT Application No. PCT/US12/29375, filed on 16 Mar. 2012, which claims the benefit of U.S. Provisional Patent Application No. 61/453,667, filed on 17 Mar. 2011, the contents of each of which applications are incorporated herein by reference in their entirety.

US Referenced Citations (183)
Number Name Date Kind
4546143 Weil Oct 1985 A
5019062 Ryan May 1991 A
5306487 Karapasha Apr 1994 A
5817300 Cook Oct 1998 A
5860959 Gent Jan 1999 A
6329465 Takahashi Dec 2001 B1
6485476 von Dyck Nov 2002 B1
6605304 Wellinghoff Aug 2003 B1
6617016 Zhang Sep 2003 B2
6852100 Gent Feb 2005 B1
6946182 Allgeuer Sep 2005 B1
6946522 Jacob Sep 2005 B2
7056971 Varma Jun 2006 B2
7060753 Jacob Jun 2006 B2
7629406 Qian Dec 2009 B2
8323254 Tsai Dec 2012 B2
10166137 Nguyen-Demary Jan 2019 B2
10207076 Foley et al. Feb 2019 B2
10322024 Chang Jun 2019 B2
10426584 McClurg Oct 2019 B2
10426654 Ugarte Oct 2019 B2
10426918 Foley et al. Oct 2019 B2
10426919 Erbey, II et al. Oct 2019 B2
10434282 Kearns et al. Oct 2019 B2
10441454 Tanghoej et al. Oct 2019 B2
10449083 Pierson Oct 2019 B2
10449327 Overtoom Oct 2019 B2
10449328 Tanghoej et al. Oct 2019 B2
10449329 Foley et al. Oct 2019 B2
10463466 Cullison Nov 2019 B2
10463833 Clarke et al. Nov 2019 B2
10470861 Khamis et al. Nov 2019 B2
10485483 Brody Nov 2019 B1
10485644 Orr et al. Nov 2019 B2
10493230 Guldager et al. Dec 2019 B2
10493231 McMenamin et al. Dec 2019 B2
10493252 Browne et al. Dec 2019 B2
10506965 Cooper et al. Dec 2019 B2
10512713 Erbey, II et al. Dec 2019 B2
10531894 Connors et al. Jan 2020 B2
10531976 Palmer Jan 2020 B2
10548523 Ahmadi et al. Feb 2020 B2
10569046 Steindahl et al. Feb 2020 B2
10569047 Farrell et al. Feb 2020 B2
10569051 Conway et al. Feb 2020 B2
10575935 Wei et al. Mar 2020 B2
10588774 Alhaqqan Mar 2020 B2
10589061 Palmer Mar 2020 B2
10589093 Imran Mar 2020 B2
10610344 Shapiro et al. Apr 2020 B2
10610664 Erbey, II et al. Apr 2020 B2
10617843 Paz Apr 2020 B2
10631788 Brody Apr 2020 B2
10639451 Kearns et al. May 2020 B2
10639452 Linares et al. May 2020 B2
10646688 Hannon et al. May 2020 B2
10667894 Forsell Jun 2020 B2
10668249 Douglas et al. Jun 2020 B2
10675134 Herrera et al. Jun 2020 B2
10675435 Herrera et al. Jun 2020 B2
10682214 Sufyan et al. Jun 2020 B2
10690655 Duval Jun 2020 B2
10702671 Terry Jul 2020 B2
10709819 Littleton et al. Jul 2020 B2
D893706 Lessmann Aug 2020 S
10736491 Truckai Aug 2020 B2
10737057 Mikhail et al. Aug 2020 B1
10744298 Bello et al. Aug 2020 B1
10751493 Gregory et al. Aug 2020 B2
10758704 Hickmott et al. Sep 2020 B2
10765833 Kearns Sep 2020 B2
10765834 Erbey, II et al. Sep 2020 B2
10772755 Gregory Sep 2020 B2
10780243 Reyes Sep 2020 B2
10780244 Conway et al. Sep 2020 B2
10780245 Schonfeldt Sep 2020 B2
10807287 Rolsted et al. Oct 2020 B2
10814097 Palmer Oct 2020 B2
11191661 Tsai Dec 2021 B2
11351054 Chang Jun 2022 B2
20020055594 Roux May 2002 A1
20020119301 Zhang Aug 2002 A1
20030018293 Tanghoj et al. Jan 2003 A1
20050043715 Nestenborg et al. Feb 2005 A1
20060163097 Murray et al. Jul 2006 A1
20060173430 Lee Aug 2006 A1
20070237916 Rasmussen Oct 2007 A1
20080103463 Tsai May 2008 A1
20090088711 Shelley Apr 2009 A1
20090137985 Tanghoej et al. May 2009 A1
20090216207 Nielsen Aug 2009 A1
20100324535 Triel Dec 2010 A1
20110052737 Florence Mar 2011 A1
20110190736 Young et al. Aug 2011 A1
20110224653 Torstensen Sep 2011 A1
20130138135 Rosen et al. May 2013 A1
20130161208 Gustavsson Jun 2013 A1
20130161227 Gustavsson Jun 2013 A1
20130261608 Tanghoj et al. Oct 2013 A1
20140066905 Young Mar 2014 A1
20140207094 Chang Jul 2014 A1
20140288517 Tsai Sep 2014 A1
20140336569 Gobel Nov 2014 A1
20140378951 Dye Dec 2014 A1
20150133898 Murray et al. May 2015 A1
20150273180 Schonfeldt Oct 2015 A1
20150273747 Montes de Oca Balderas et al. Oct 2015 A1
20150290421 Glickman et al. Oct 2015 A1
20150297862 Sadik et al. Oct 2015 A1
20150320970 Foley et al. Nov 2015 A1
20160067445 Murray et al. Mar 2016 A1
20160184551 Nyman et al. Jun 2016 A1
20160206469 Prezelin Jul 2016 A1
20160287759 Clarke et al. Oct 2016 A1
20160317715 Rostami et al. Nov 2016 A1
20160325903 Doerschner et al. Nov 2016 A1
20170000978 Murray et al. Jan 2017 A1
20170021128 Erbey, II et al. Jan 2017 A1
20170105826 Erikstrup Apr 2017 A1
20170348137 Hvid et al. Dec 2017 A1
20170348138 Hvid et al. Dec 2017 A1
20180015250 Tsukada et al. Jan 2018 A1
20180021481 Yin et al. Jan 2018 A1
20180050173 Kearns Feb 2018 A1
20180071482 Fitzpatrick et al. Mar 2018 A1
20180369474 Falleboe et al. Dec 2018 A1
20190099583 Charles et al. Apr 2019 A1
20190151134 Tsai May 2019 A1
20190224402 Henry et al. Jul 2019 A1
20190231581 Chang Aug 2019 A1
20190240060 He et al. Aug 2019 A1
20190247549 Nielsen Aug 2019 A1
20190314044 Long et al. Oct 2019 A1
20190314188 Barrientos Oct 2019 A1
20190314190 Sanchez et al. Oct 2019 A1
20190321587 McMenamin et al. Oct 2019 A1
20190321589 Bonneau Oct 2019 A1
20190358075 Scharich, III et al. Nov 2019 A1
20190358435 Andersin et al. Nov 2019 A1
20190365561 Newton et al. Dec 2019 A1
20190366038 Denman et al. Dec 2019 A1
20190374324 Luleci Dec 2019 A1
20190381291 Feld Dec 2019 A1
20190388659 Ruel Dec 2019 A1
20200001045 McIntyre Jan 2020 A1
20200001049 House Jan 2020 A1
20200016380 Murray et al. Jan 2020 A1
20200022636 Suehara et al. Jan 2020 A1
20200030135 Woodyard Jan 2020 A1
20200030582 Dong Jan 2020 A1
20200030595 Boukidjian et al. Jan 2020 A1
20200037832 Wang et al. Feb 2020 A1
20200054800 Wilbourn et al. Feb 2020 A1
20200094017 Erbey, II et al. Mar 2020 A1
20200101280 Peddicord Apr 2020 A1
20200129731 Brar et al. Apr 2020 A1
20200139109 Imran May 2020 A1
20200146799 Connors et al. May 2020 A1
20200146871 Palmer May 2020 A1
20200163543 Schutt et al. May 2020 A1
20200163699 Bacich et al. May 2020 A1
20200179644 Gukdbaek Jun 2020 A1
20200179665 Orr et al. Jun 2020 A1
20200188631 Hannon et al. Jun 2020 A1
20200206389 Vange Jul 2020 A1
20200206411 Henry et al. Jul 2020 A1
20200206470 Orr et al. Jul 2020 A1
20200215303 Erbey, II et al. Jul 2020 A1
20200222220 Kappus et al. Jul 2020 A1
20200222659 Schertiger et al. Jul 2020 A1
20200222660 Erbery, II et al. Jul 2020 A1
20200222674 Inoue et al. Jul 2020 A1
20200230349 McMenamin et al. Jul 2020 A1
20200230382 Siebert Jul 2020 A1
20200246587 Tal et al. Aug 2020 A1
20200254215 Portela et al. Aug 2020 A1
20200261692 Palmer Aug 2020 A1
20200262868 Ricca et al. Aug 2020 A1
20200268947 Erbey, II et al. Aug 2020 A1
20200276410 Son Sep 2020 A1
20200282092 Paul et al. Sep 2020 A1
20200330724 Mikhail et al. Oct 2020 A1
20220087850 Tsai Mar 2022 A1
Foreign Referenced Citations (19)
Number Date Country
3001976 Apr 2016 EP
3100758 Dec 2016 EP
3315159 May 2018 EP
3351208 Jul 2018 EP
0134685 May 2001 WO
2007106671 Sep 2007 WO
2008052018 May 2008 WO
2009048375 Apr 2009 WO
2018134591 Jul 2018 WO
2018143487 Aug 2018 WO
2019014344 Jan 2019 WO
2019038732 Feb 2019 WO
2019038734 Feb 2019 WO
2019106581 Jun 2019 WO
2019123004 Jun 2019 WO
2019184222 Oct 2019 WO
2019222644 Nov 2019 WO
2019229597 Dec 2019 WO
2020015804 Jan 2020 WO
Non-Patent Literature Citations (2)
Entry
Extended European Search Report; European Patent Office; European Patent Application No. 19218078.4; dated Apr. 21, 2020; 10 pages.
Chinese Office Action; China Patent Office; Chinese Patent Application No. 201810218760.8; dated Aug. 14, 2020; 19 pages.
Related Publications (1)
Number Date Country
20220087850 A1 Mar 2022 US
Provisional Applications (1)
Number Date Country
61453667 Mar 2011 US
Continuations (2)
Number Date Country
Parent 16186003 Nov 2018 US
Child 17534550 US
Parent 14005814 US
Child 16186003 US